# IFM 2018-04 (NCT03606577)

> An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03606577
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Nantes University Hospital
- Conditions: Multiple Myeloma
- Interventions: Carfilzomib; Daratumumab; Lenalidomide; Dexamethasone
- Enrollment: 50
- Primary outcome: Percentage of patients receiving the second Autologous Stem Cell Transplant

## Commentary we found

- X threads: 9
- YouTube: 5
- Podcasts: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=ifm-2018-04-nct03606577

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03606577", "email": "<work email>"}; the inbox owner confirms by the emailed link.